Kick-starting the cancer-immunity cycle by targeting CD40

Forskningsoutput: TidskriftsbidragDebate/Note/Editorial

Abstract

Stimulation of CD40 on dendritic cells to expand and activate tumor-specific T cells and generate anticancer immunity is an attractive therapeutic approach. Since CD40 agonists exert their effects upstream of checkpoint inhibitors, including PD-1 or PD-L1 antagonists, they are ideal candidates for combination regimens.

Detaljer

Författare
  • Peter Ellmark
  • S. M. Mangsbo
  • C. Furebring
  • T. H. Totterman
  • P. Norlen
Enheter & grupper
Externa organisationer
  • Alligator Bioscience AB
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Immunologi inom det medicinska området

Nyckelord

Originalspråkengelska
Sidor (från-till)e1011484
TidskriftOncoImmunology
Volym4
Utgåva nummer7
StatusPublished - 2015
PublikationskategoriForskning
Peer review utfördNej